# Karuna Therapeutics, Inc. – Consensus ‘hold’ rating and -1.7% Downside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.consensus-hold-rating-and-1.7-downside-potential-4/4121157253
- Published: 2024-05-17T14:38:13+01:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** which can be found using ticker (KRTX) have now 12
market analysts covering the stock. The analyst consensus now points to a rating
of ‘hold’. The target price High/Low ranges between $330.00 and $260.00 suggesting
an average Analsyt target price of $324.17. Now with the previous closing price 
of $329.83 this now indicates there is a potential downside of -1.7%. There is a
50 day moving average of $317.71 and the 200 day MA is $230.08. The total market
capitalization for the company now stands at 12.60B. The stock price is currently
at: $329.83 USD

 The potential market cap would be $12,383,066,469 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of $0.02 and a -24.71% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on: